A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
Unknown statusNot applicableNCT02487888
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the impact of genetic testing on healthcare decisions and patient outcomes for patients suffering from pain, cardiovascular problems, Arthritis, Type II Diabetes, and/or Mental Health disorders. Results of genetic testing will also be compared with the clinical outcome measures collected to discover novel genetic factors that may influence patient care.
Study details
- Official title
- Randomized, Blinded, Controlled Trial to EValuate the EcOnomic and ClinicaL Outcomes of Utilizing Genetic Testing to Improve Therapeutic Decision-Making COmpared to Empiric Prescribing as the StaNdard of Care
- Conditions
- Pain
- Chronic Pain
- Mental Disorders
- Cardiovascular Diseases
- Diabetes Mellitus, Type 2
- Arthritis
- Interventions
- Other: Unblinded to Genetic Testing Results
- Other: Blinded to Genetic Testing Results
- Sponsor
- Proove Bioscience, Inc.
- Start date
- 2014-09
- Primary completion
- 2016-10
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 31
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Provide signed and dated informed consent form * Willing to comply with all study procedures and be available for the duration of the study * Male or Female, at least 18 years of age * Currently taking or a candidate for medication * Documented or recent complaint within 90 days with initial date of onset Exclusion Criteria: * Severe hepatic or renal disease (where current pharmaceutical dosing is affected and/or requires adjustment of standard dosing prior to PGx testing) * Significant diminished mental capacity that is unable to understand the protocol, surveys and questionnaires; unable to read/write English or Spanish. * Recent febrile illness that precludes or delays participation by more than 1 month * Pregnancy or lactation * Participation in a clinical study that may interfere with participation in this study * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02487888